Biodesix strengthens financial position with equity issuance and amendment to term loan

Boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 6,508,376 common shares on april 7, 2022 in a private placement offering that raised approximately $11.7 million in net proceeds to, among other things, fund the partial repayment of its existing term loan and general corporate purposes, including our strategic growth. in addition, the company entered into a third amendment to its
BDSX Ratings Summary
BDSX Quant Ranking